Increased expression of galectin-1 is associated with human oral squamous cell carcinoma development

Ding, Yong Hong; Dong, Jing; Chen, Lili; Zhang, Handong

doi:10.3892/or_00000312

Cited by 29 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, oncogene transformation induces CCR5 expression, and the subpopulation of cells that express a functional CCR5 also displays increased cell migration [61] and invasiveness [62]. A microarray analysis on 2,254 human breast cancer specimens found increased expression of CCL5 and its receptor CCR5, but not CCR3, in the basal and HER-2 genetic subtypes [62].…”

Section: The Ccl5/ccr5 Axis In Solid Tumorsmentioning

confidence: 99%

The Inflammatory Chemokine CCL5 and Cancer Progression

Aldinucci

Colombatti

2014

Mediators of Inflammation

371

325

View full text Add to dashboard Cite

Until recently, inflammatory chemokines were viewed mainly as indispensable “gate keepers” of immunity and inflammation. However, updated research indicates that cancer cells subvert the normal chemokine system and these molecules and their receptors become important constituents of the tumor microenvironment with very different ways to exert tumor-promoting roles. The CCR5 and the CCL5 ligand have been detected in some hematological malignancies, lymphomas, and a great number of solid tumors, but extensive studies on the role of the CCL5/CCR axis were performed only in a limited number of cancers. This review summarizes updated information on the role of CCL5 and its receptor CCR5 in cancer cell proliferation, metastasis, and the formation of an immunosuppressive microenvironment and highlights the development of newer therapeutic strategies aimed to inhibit the binding of CCL5 to CCR5, to inhibit CCL5 secretion, or to inhibit the interactions among tumor cells and the microenvironment leading to CCL5 secretion.

show abstract

Section: The Ccl5/ccr5 Axis In Solid Tumorsmentioning

confidence: 99%

The Inflammatory Chemokine CCL5 and Cancer Progression

Aldinucci

Colombatti

2014

Mediators of Inflammation

371

325

View full text Add to dashboard Cite

show abstract

“…However, the adipokines like TNF-α, IL-6, IL-8, and MCP-1 have been reported to promote tumor growth [211]. The role of ASCs in regulating breast cancer is confounding due to varied nature of secreted adipokines, such as CCL5, which enhances the motility of MCF-7 breast cancer cell in vitro [212]. In contrast to this, another study reported that high density ADSC-CM inhibited the MCF-7 [213].…”

Section: Asc Secretome and Its Therapeutic Effectmentioning

confidence: 99%

Revisiting the Advances in Isolation, Characterization and Secretome of Adipose-Derived Stromal/Stem Cells

Dubey

Mishra²,

Dubey

et al. 2018

IJMS

View full text Add to dashboard Cite

Adipose-derived stromal/stem cells (ASCs) seems to be a promising regenerative therapeutic agent due to the minimally invasive approach of their harvest and multi-lineage differentiation potential. The harvested adipose tissues are further digested to extract stromal vascular fraction (SVF), which is cultured, and the anchorage-dependent cells are isolated in order to characterize their stemness, surface markers, and multi-differentiation potential. The differentiation potential of ASCs is directed through manipulating culture medium composition with an introduction of growth factors to obtain the desired cell type. ASCs have been widely studied for its regenerative therapeutic solution to neurologic, skin, wound, muscle, bone, and other disorders. These therapeutic outcomes of ASCs are achieved possibly via autocrine and paracrine effects of their secretome comprising of cytokines, extracellular proteins and RNAs. Therefore, secretome-derivatives might offer huge advantages over cells through their synthesis and storage for long-term use. When considering the therapeutic significance and future prospects of ASCs, this review summarizes the recent developments made in harvesting, isolation, and characterization. Furthermore, this article also provides a deeper insight into secretome of ASCs mediating regenerative efficacy.

show abstract

“…Another MSC-secreted pro-metastasis cytokine, CCL5 (RANTES), can be secreted upon interaction with cancer cells and is associated with tumor progression and invasion in various cancers [73, 87, 100, 142–144]. CCL5 can be secreted by both BM-MSC and ASC [100, 144] and displays pro-proliferative activities on breast cancer cell lines [145, 146]. Other MSC-secreted factors upregulated during interactions with cancer cells and exhibiting potent effect on tumor cells include BMP2, CXCL1, CXCL5, CXCL6, CXCL7, EGF, IL4, IL8, IL10, IL17b or S100A4.…”

Section: The Msc Secretome and Cancer Cellsmentioning

confidence: 99%

Mesenchymal stem cell secretome and regenerative therapy after cancer

et al. 2013

View full text Add to dashboard Cite

Cancer treatment generally relies on tumor ablative techniques that can lead to major functional or disfiguring defects. These post-therapy impairments require the development of safe regenerative therapy strategies during cancer remission. Many current tissue repair approaches exploit paracrine (immunomodulatory, pro-angiogenic, anti-apoptotic and pro-survival effects) or restoring (functional or structural tissue repair) properties of mesenchymal stem/stromal cells (MSC). Yet, a major concern in the application of regenerative therapies during cancer remission remains the possible triggering of cancer recurrence. Tumor relapse implies the persistence of rare subsets of tumor-initiating cancer cells which can escape anti-cancer therapies and lie dormant in specific niches awaiting reactivation via unknown stimuli. Many of the components required for successful regenerative therapy (revascularization, immunosuppression, cellular homing, tissue growth promotion) are also critical for tumor progression and metastasis. While bidirectional crosstalk between tumorigenic cells (especially aggressive cancer cell lines) and MSC (including tumor stroma-resident populations) has been demonstrated in a variety of cancers, the effects of local or systemic MSC delivery for regenerative purposes on persisting cancer cells during remission remain controversial. Both pro- and anti-tumorigenic effects of MSC have been reported in the literature. Our own data using breast cancer clinical isolates have suggested that dormant-like tumor-initiating cells do not respond to MSC signals, unlike actively dividing cancer cells which benefited from the presence of supportive MSC. The secretome of MSC isolated from various tissues may partially diverge, but it includes a core of cytokines (i.e. CCL2, CCL5, IL-6, TGFβ, VEGF), which have been implicated in tumor growth and/or metastasis. This article reviews published models for studying interactions between MSC and cancer cells with a focus on the impact of MSC secretome on cancer cell activity, and discusses the implications for regenerative therapy after cancer.

show abstract

Increased expression of galectin-1 is associated with human oral squamous cell carcinoma development

Cited by 29 publications

References 24 publications

The Inflammatory Chemokine CCL5 and Cancer Progression

The Inflammatory Chemokine CCL5 and Cancer Progression

Revisiting the Advances in Isolation, Characterization and Secretome of Adipose-Derived Stromal/Stem Cells

Mesenchymal stem cell secretome and regenerative therapy after cancer

Contact Info

Product

Resources

About